Award Data

The Oak Ridge National Laboratory (ORNL) Neutron Imaging Facility will build a Talbot- Lau interferometer for advanced imaging projects, including inspection of additive manufactured components- This SBIR seeks to enhance the ORNL interferometer with novel optics, enabling the interferometer to operate in both Talbot-Lau and the recently invented far-field mode- Dual-mode operation is an ORNL goal ...

Abstract – The goal of this Phase II clinical trial application will be to evaluate 4-demethyl-4- cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) as anticancer therapy for adolescents and young adults (AYA) with cancer involving the brain in a Phase II clinical trial. DM-CHOC-PEN (Fig. 1) is a polychlorinated pyridine cholesteryl carbonate (Fig. 1) that is lipophilic, electrically neural, is ab ...

PROJECT ABSTRACT The goal of this Phase I STTR proposal is to develop and establish preclinical proof of concept for the first double chimeric peptide vaccine feasible for human use that protects against disseminated candidiasisDisseminated candidiasis is the third leading cause of nosocomial bloodstream infections in the USwithcases per year and associated healthcare costs of $billionanddespite t ...

Abstract Development ofD organotypic cellular models utilizing animal cells is important for the validation of these systems by direct comparison to animal dataA few organizations have been successful in providing such assays for various organ systemsHoweverdevelopment of peripheral nerve assays is laggingCommonly used peripheral neural culture preparations are not predictive of clinical toxicityp ...

PROJECT SUMMARY Alzheimer s diseaseADis a progressive neurodegenerative disorder of the elderly that afflicts aboutmillion patients globally and overmillion Americans in the USDespite the considerable research effort to preventtreator cure the diseaseeffective strategies remain lackingThe accumulation of amyloidAin the brain blood vessels can result in the development of cerebral amyloid angiopath ...

Project Summary Fulvestrant is the only FDA approved selective estrogen receptor downregulatorSERDindicated for advanced metastatic breast cancer that has progressed after or during tamoxifen or aromatase inhibitorAItreatmentIn July and Augustfulvestrant was approved as a first line endocrine agent for breast cancer patients by the European Medicines AgencyEMAand US FDArespectivelyHoweverthe drug ...